ACINO HOLDING AG
Previous company name
SCHWEIZERHALL HOLDING AG
Name change date
Schweizerhall Holding AG is a holding company active in the pharmaceutical and chemical industries. The company, through the Schweizerhall Group, is a leading specialist in chemicals, healthcare and biotechnology. With sales exceeding CHF 200 million, Schweizerhall is the number one chemicals trader and distributor in Switzerland, as well as a leading group in specialty pharmaceuticals and value added generics supplying major marketers of pharmaceutical products throughout Europe. Schweizerhall Holding was incorporated in 1836.
Through its subsidiaries, Schweizerhall Holding develops, registers, and manufactures generic and patent-protected specialty pharmaceuticals, focusing on solid slow-release forms and on therapeutic systems for transdermal applications such as patches and biodegradable implants. Its business activity is split into two main divisions: business unit pharma division and business unit chemicals. The business unit pharma division specializes in the development, registration and approval, production and packaging of pharmaceuticals which are no longer operates under patent protection. This unit supplies many firms throughout Europe. The business unit chemicals division is a supplier of chemical raw materials, intermediates, specialty chemicals and customized mixtures within comprehensive supply chain solutions.
Registered and headquartered in Basle, Switzerland, Schweizerhall Holding AG is listed on the SWX Swiss Exchange (SWHN). The company is the number one chemicals trader and distributor in Switzerland. Complementing its industrial activities, the company leverages its vast industry experience and sector know-how to actively manage a healthcare and biotechnology portfolio. Furthermore, the company offers global sourcing, optimal storage, packaging, quality assurance, just-in-time delivery, disposal and recycling.
In 2006, Schweizerhall acquired Novosis AG, which is engaged in the development of value-added products for selected applications to generics companies. Schweizerhall also divested its chemicals distribution business. Besides Novosis, Cimex is also a business unit of the Schweizerhall Group. Cimex is one of Europe’s leading full-service providers in the business-to-business segment of the generics industry. In addition to the development and manufacture of specialty generics, Cimex provides complementary services for its customers, such as registration, sourcing of active ingredients, packaging and logistics.
Aside from Europe, Schweizerhall Holding’s subsidiaries are based in the United States of America and India, among others.
Formerly known as Schweizerhall Holding AG, the Company is a company that is active in generics and pharmaceutical specialties. The Company’s activities specializes in the development, registration, approval, manufacturing and packaging of pharmaceuticals and generics in Europe and supplier of chemical raw materials, intermediates, specialty chemicals and customized mixtures on the Swiss market. It is operative in two business units: Cimex and Novosis. Core competencies of Cimex include the development and manufacture of complex generics, as well as complementary services for its customers, such as registration, sourcing of active ingredients, packaging and logistics. Novosis specializes in the development and manufacture of transdermal and implantable advanced drug delivery systems, such as therapeutic controlled release patches and inserts primarily for established active ingredients. Novosis possesses a development pipeline with products in the indication areas of pain and cancer. Its core brand is Fentanyl, a patch for the treatment of chronic pain. The Company operates in Switzerland, Germany, United Kingdom, Ireland, France, Rest of Europe and Rest of World.
Description and history
The Company was founded in 1890. The Company’s principal activity is that of a Holding Company with interests in generics and pharmaceutical specialties. The Company’s shares were listed on Swiss Stock Exchange on May 10, 2005, under the code of 0021190902. The Company is headquartered in Basel, Switzerland.
1890 Foundation of Chemische Fabrik Schweizerhall (CFS) with share capital of CHF 600,000.00.
1900 – 1945 Fertilizer production and build-up of chemicals distri- bution in Switzerland
1945 – 1970 Giving-up of production activities
Expansion of chemicals distribution, leading position in Switzerland
1971 – 1994 Internationalization of trading activities through acquisitions in France, USA, The Netherlands, Singapore and Hong Kong
Build-up of a luxury goods division
1986 Holding company structure with operational activities in the trade of basic and specialty chemicals, fertilizers, pharmaceutical active substances and intermediates; marketing of perfumes
September 2008: The Company’s name has been changed from Schweizerhall Holding AG into Acino Holding AG.
Description in German
Schweizerhall ist eine Beteiligungsgesellschaft mit Schwerpunktengagements in Chemie, Life Sciences, Biotechnologie und Pharma.
Schweizerhall eroffnet privaten und institutionellen Aktionaren den Zugang zu fuhrenden Venture-Capital-Gesellschaften und aufstrebenden, nicht borsenkotierten Forschungs- und Entwicklungsunternehmen. Daruber hinaus investiert Schweizerhall im Sinne eines Risikoausgleichs in Gesellschaften, die borsenkotiert sind, und uber einen jahrelangen Erfolgsausweis und eine uberragende Marktstellung verfugen.
Mit ihren Beteiligungen strebt Schweizerhall eine mittel- bis langfristige Wertsteigerung ihrer Engagements an. Die Schweizerhall Holding AG ist an der Schweizer Borse (SWX) kotiert.
Holding company engaged development, registration and approval, production and packaging of pharmaceuticals and distibution of chemicals
US SIC Code
City province or state postal code
Phone: +49 61 338 60 00
Fax: +49 61 338 60 80
Country address: SWITZERLAND
Website url: www.acino-pharma.com